Magazine · Issue 01 · Competitiveness
The drug makers are committing. Europe is waiting.
For years, Europe’s low medicine prices and its patchwork of national markets were things it could live with. America’s new pricing rules has turned both against it. Bas Amesz, who a decade ago proposed a different way to pay for medicines, argues the shock is Europe’s chance to buy innovation as a single bloc, and that its instinct to wait is the real danger.
